The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.
EMA: Indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease. FDA: Indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.
Melanoma
Cutaneous Melanoma
-
OPTiM
3
ADJUSTMENTS
FINAL SCORE
F1
3
Avelumab
-
Single arm (Phase II)
Adult patients with metastatic Merkel cell carcinoma (MCC)
Skin Cancers
Merkel cell carcinoma
-
JAVELIN Merkel 200 (Part B - treatment-naïve patients)
4
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
2
Trastuzumab
-
Chemotherapy
Patients with HER2-positive early breast cancer following surgery, ChT (neoadjuvant or adjuvant) and RT (if applicable)
Breast Cancer
Early Breast Cancer
HER2+
HERA
A
ADJUSTMENTS
FINAL SCORE
F1
1
Pertuzumab
Trastuzumab + docetaxel
Trastuzumab + docetaxel (Randomised phase II study)
Neo-adjuvant HER2 overexpressed invasive ductal breast
Breast Cancer
Early Breast Cancer
HER2+
NeoSphere
C
ADJUSTMENTS
FINAL SCORE
F1
3
Trastuzumab emtansine (T-DM1)
-
Lapatinib + capecitabine
As a single agent for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy
Breast Cancer
Breast Cancer
HER2+
EMILIA
4
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
2
Pertuzumab
Trastuzumab + docetaxel
Trastuzumab + docetaxel + placebo
HER2-positive locally recurrent unresectable or metastatic breast cancer with no prior anti-HER2 therapy or ChT for metastatic disease
Breast Cancer
Breast Cancer
HER2+
CLEOPATRA
4
PRELIMINARY SCORE
OS
5
ADJUSTMENTS
FINAL SCORE
F1
2
Lapatinib
Trastuzumab
Lapatinib
HER2-positive, hormone receptor-negative metastatic breast cancer after progression on prior trastuzumab + ChT regimen(s)
Breast Cancer
Breast Cancer
HER2+ HR-
EGF104900
4
PRELIMINARY SCORE
OS
5
ADJUSTMENTS
FINAL SCORE
F1
2
Palbociclib
Fulvestrant
Fulvestrant + placebo
Hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer previously treated with endocrine therapy
Breast Cancer
Breast Cancer
HR+ HER2-
PALOMA-3
4
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
2
Palbociclib
Letrozole
Letrozole + placebo
First-line postmenopausal, ER-positive, HER2-negative locally advanced metastatic breast cancer
Breast Cancer
Breast Cancer
HR+ HER2-
PALOMA-2
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Palbociclib
Letrozole
Letrozole (Randomised phase II study)
1st line metastatic HR+ HER2-
Breast Cancer
Breast Cancer
HR+ HER2-
PALOMA-1/TRIO-18
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Treatment Setting
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
esmo.mcbs.table.heading.visualisation
esmo.mcbs.table.heading.visualisation
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.